Ebb in Flow: Sickle Cell Disease Draws Multiple Challenges to the Surface (30% off for AAMA Members in June)-Ebb in Flow: Sickle Cell Disease Draws Multiple Challenges to the Surface

Ebb in Flow: Sickle Cell Disease Draws Multiple Challenges to the Surface

Pdf Summary

Sickle cell disease (SCD) is an inherited blood disorder that affects millions worldwide and about 100,000 Americans, most of whom in the U.S. are Black or African American. It causes red blood cells to become rigid, crescent-shaped, and prone to clogging small blood vessels, which leads to pain, tissue damage, anemia, infections, stroke, and organ disease. SCD includes several related genetic conditions, with sickle cell anemia being the most common and often most severe.<br /><br />Early diagnosis and lifelong, comprehensive care are essential. Newborn screening is standard in the U.S., and early childhood treatments such as penicillin prophylaxis, vaccination, and stroke screening have greatly improved survival. Children with SCD are at high risk for infection and stroke, so care often includes transcranial Doppler screening, hydroxyurea, antibiotics, and specialized vaccinations.<br /><br />Pain crises are the hallmark of SCD and often drive emergency care visits. However, patients—especially adults—frequently face undertreatment, delayed triage, skepticism, and stigma, including racial bias and assumptions of drug-seeking behavior. Effective management may require opioids for acute pain, plus supportive strategies and a clear pain plan shared with emergency staff.<br /><br />Because SCD affects many organs, patients often need coordinated care from hematologists, primary care clinicians, and multiple specialists, along with psychosocial support and patient navigation. Complications such as iron overload, priapism, kidney disease, and pulmonary problems require proactive monitoring.<br /><br />Treatment options are expanding. Bone marrow transplant can cure some patients, especially children, and newer haploidentical transplant approaches and FDA-approved gene therapies offer hope for broader use in the future. The article emphasizes that better education, improved access to care, and reduced bias are essential to help people with SCD live longer, healthier lives.

Keywords

sickle cell disease

sickle cell anemia

inherited blood disorder

red blood cells

pain crises

hydroxyurea

newborn screening

stroke prevention

bone marrow transplant

gene therapy